INTRODUCTION
============

Inflammation is produced in response to infections caused by various stimuli, including microbial pathogens, chemicals or damaged cells. Chronic inflammation is highly associated with diseases, such as cancer, arthritis, and age-related diseases ([@b1-bmb-51-654], [@b2-bmb-51-654]). Macrophages are important immune cells, which ultimately trigger inflammatory responses via production of nitric oxide (NO), inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β and IL-6 ([@b3-bmb-51-654], [@b4-bmb-51-654]). Lipopolysaccharide (LPS), one of the most powerful inflammatory stimulants, activates toll like receptors (TLR4) on macrophages, and eventually triggers the activation of nuclear factor-kappaB (NF-κB) and mitogen activated protein kinase (MAPK) pathways ([@b5-bmb-51-654], [@b6-bmb-51-654]). NF-κB plays an important role in inflammation, apoptosis, cancer ([@b7-bmb-51-654]), and phosphorylation of MAPKs, such as extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK) in LPS-induced macrophages involved in the activation of NF-κB ([@b1-bmb-51-654], [@b8-bmb-51-654]). Therefore, inhibition of NF-κB and MAPKs activation is an important therapeutic strategy for inflammatory-related diseases ([@b4-bmb-51-654], [@b9-bmb-51-654]).

Antioxidant 1 (ATOX1) is a small protein, highly expressed in the cerebral cortex and hippocampus. It plays a crucial role as a copper chaperone ([@b10-bmb-51-654], [@b11-bmb-51-654]). This protein has also been reported to protect cells against oxidative damage induced by hydrogen peroxide and streptozotocin (STZ) ([@b12-bmb-51-654], [@b13-bmb-51-654]). Changes in ATOX1 expression levels may contribute to the inflammatory response and antioxidant defense in cells ([@b14-bmb-51-654], [@b15-bmb-51-654]). In addition, inactivation of ATOX1 markedly increases cell sensitivity to stressors ([@b16-bmb-51-654]). In contrast, other studies have suggested that ATOX1 may act as a therapeutic protein in cancer and neuronal diseases ([@b17-bmb-51-654]--[@b19-bmb-51-654]). However, the effects of ATOX1 on the inflammatory response remains unclear.

Since protein transduction domains (PTDs) are known to be cell-permeable, PTDs are generally used to examine the effects of target proteins for treatment of various diseases. Previous studies have shown that PTD fusion proteins have the ability to transduce into cells and these proteins protected ROS-induced cell death ([@b20-bmb-51-654]--[@b23-bmb-51-654]). We also have demonstrated that Tat-ATOX1 transduced into cells protected against oxidative stress- or STZ-induced cell death ([@b13-bmb-51-654], [@b24-bmb-51-654]). In this study, we determined the effects of Tat-ATOX1 in LPS-induced Raw 264.7 cells and in a TPA-induced mouse model.

RESULTS AND DISCUSSION
======================

Transduction of Tat-ATOX1 into Raw 264.7 cells
----------------------------------------------

Tat-ATOX1 and control ATOX1 proteins were prepared as described previously ([@b13-bmb-51-654], [@b24-bmb-51-654]). To identify the transduction of fusion protein, cells were pretreated with varying concentrations (0.01--0.3 μM) of Tat-ATOX1 or with the same concentration over differing time periods (15--60 min). Next, the stability of Tat-ATOX1 was investigated in the cells. [Fig. 1A--1C](#f1-bmb-51-654){ref-type="fig"} shows transduction of protein, gradual degradation and persistence for up to 15 h in the cells. Further, we determined the intracellular distribution of transduced Tat-ATOX1 by DAPI- and Alexa Fluor 488-staining. Fluorescence signals of Tat-ATOX1 were observed in the cytoplasm and nucleus in the cells ([Fig. 1D](#f1-bmb-51-654){ref-type="fig"}). These results indicate that Tat-ATOX1 was transduced into Raw 264.7 cells.

Several studies have shown that PTD fused protein transduction can be used as a tool for the intracellular application of therapeutic proteins ([@b20-bmb-51-654]--[@b23-bmb-51-654]). In previous studies, we have shown that Tat fused proteins transduced into different cell lines ([@b13-bmb-51-654], [@b24-bmb-51-654]--[@b27-bmb-51-654]). Also, we investigated the effects of transduced Tat-ATOX1 against LPS-induced oxidative stress in Raw 264.7 cells. As shown in [Fig. 1E](#f1-bmb-51-654){ref-type="fig"}, the production of intracellular ROS was drastically increased in LPS-exposed Raw 264.7 cells, whereas it was markedly reduced in cells exposed to transduced Tat-ATOX1. Our observations are consistent with other reports showing that ROS levels were markedly increased in ATOX1^−/−^ mice, suggesting ATOX1 is involved in ischemia-induced endothelial ROS production ([@b14-bmb-51-654]). Similarly, several studies have demonstrated that overexpression of ATOX1 inhibited neuronal cell death caused by hydrogen peroxide via reduction of cellular ROS levels. In addition, inactivation of ATOX1 has been shown to markedly increase cell sensitivity to various stressors ([@b16-bmb-51-654], [@b17-bmb-51-654]).

Effects of Tat-ATOX1 on LPS-induced inflammatory responses in Raw 264.7 cells
-----------------------------------------------------------------------------

To investigate whether Tat-ATOX1 suppressed LPS-induced inflammatory responses in cells, pro-inflammatory mediator protein levels were examined. As shown in [Fig. 2A](#f2-bmb-51-654){ref-type="fig"}, COX-2 and iNOS expressions were significantly increased in LPS-exposed cells. However, these expressions were markedly reduced when cells were pretreated with Tat-ATOX1, and control ATOX1 did not produce any effects.

Next, we examined the effect of Tat-ATOX1 against LPS-induced NF-κB and MAPK activation in Raw 264.7 cells. NF-κB is the major transcription factor of the inflammatory response to LPS. LPS-induced MAPK signaling pathways have been implicated in the inflammatory response through NF-κB activation ([@b28-bmb-51-654]--[@b30-bmb-51-654]). As shown in [Fig. 2B and 2C](#f2-bmb-51-654){ref-type="fig"}, phosphorylated NF-κB and MAPKs (p38, JNK, and ERK) levels were markedly increased in LPS-exposed cells. However, Tat-ATOX1 significantly reduced NF-κB and MAPKs activation whereas this activation was not affected in control ATOX1-treatment cells. These results indicate that transduced Tat-ATOX1 inhibits LPS-induced inflammatory responses by inhibition of NF-κB and MAPK activation in Raw 264.7 cells. In agreement with our results, many studies have shown that the phosphorylation levels of NF-κB and MAPKs were markedly increased in LPS-exposed cells, whereas treatment with various antiinflammatory substances markedly inhibited inflammatory responses through inhibition of COX-2 and iNOS expression, and NF-κB and MAPKs activation ([@b31-bmb-51-654]--[@b33-bmb-51-654]).

Effects of Tat-ATOX1 on skin inflammation
-----------------------------------------

Other studies have used TPA, a powerful promoter of skin inflammation, to examine skin inflammation in animal models ([@b34-bmb-51-654], [@b35-bmb-51-654]). We examined whether Tat-ATOX1 protein showed anti-inflammatory effects against TPA-induced ear edema in a mouse model. Ear thickness and weights were drastically increased in the TPA-treated groups, while topically applied Tat-ATOX1 significantly reduced TPA-induced increases in ear thickness and weights, compared to the TPA-treated groups ([Fig. 3](#f3-bmb-51-654){ref-type="fig"}). Also, we determined whether Tat-ATOX1 inhibits COX-2 and iNOS expression, as well as NF-κB and MAPKs activation in an animal model. Topically applied Tat-ATOX1 markedly inhibited COX-2 and iNOS expression ([Fig. 4A](#f4-bmb-51-654){ref-type="fig"}). Furthermore, topically applied Tat-ATOX1 inhibited the activation of NF-κB and MAPKs. However, control ATOX1 did not show the same effects ([Fig. 4B and 4C](#f4-bmb-51-654){ref-type="fig"}). These results demonstrated the protective effect of Tat-ATOX1 on TPA-induced skin inflammation. Several studies have reported that inhibitory substances of NF-κB, MAPKs, and cytokines protected against the TPA-induced inflammation and that they can be used as therapeutic agents for skin inflammatory diseases ([@b36-bmb-51-654], [@b37-bmb-51-654]). Kamiya *et al* (2018) demonstrated that overexpression of ATOX1 induced the expression of SOD3 and enhanced TPA-elicited SOD3 induction in TPA-treated THP-1 cells ([@b38-bmb-51-654]). Ha *et al* (2006) demonstrated that SOD3, an anti-oxidant protein, plays an important role in the inhibition of TPA-induced inflammation and epidermal hyperplasia by regulation of pro-inflammatory cytokines in the skin of SOD3 transgenic mice ([@b39-bmb-51-654]). Also, other studies have shown that TPA-induced cell proliferation and DNA damage were inhibited, and tumor formation was reduced in a DMBA/TPA-induced skin carcinogenesis model using overexpressed EC-SOD transgenic mice, suggesting EC-SOD plays a protective role in DMBA/TPA-induced skin carcinogenesis ([@b40-bmb-51-654]). However, further research is required to clarify the molecular mechanisms underlying function of ATOX1 in macrophages and skin inflammation.

In summary, we have shown that transduced Tat-ATOX1 markedly suppressed inflammatory responses in LPS-exposed Raw 264.7 cells and in a TPA-induced animal model by inhibition of pro-inflammatory mediator proteins, as well as activated NF-κB and MAPK, suggesting that Tat-ATOX1 may contribute to the development of therapeutic proteins for the treatment of skin inflammation.

MATERIALS AND METHODS
=====================

Materials and cell culture
--------------------------

Tat-ATOX1 and control ATOX1 protein were prepared in our laboratory as described previously ([@b13-bmb-51-654], [@b24-bmb-51-654]). Histidine, COX-2, and iNOS antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). LPS and TPA were purchased from Sigma-Aldrich (St. Louis, MO, USA). Other antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Male ICR mice (4--6 weeks old) were obtained from the Experimental Animal Center at Hallym University. All other agents were of the highest grade available, unless otherwise stated.

Raw 264.7 murine macrophage cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 20 mM HEPES/NaOH (pH 7.4), 5 mM NaHCO~3~, 10% fetal bovine serum (FBS), and antibiotics (100 μg/ml streptomycin, 100 U/ml penicillin) at 37°C under humidified conditions of 95% air and 5% CO~2~.

Purification and transduction of Tat-ATOX1 protein
--------------------------------------------------

Tat-ATOX1 protein was purified as described previously ([@b13-bmb-51-654], [@b24-bmb-51-654]). Purified Tat-ATOX1 and control ATOX1 were treated with Detoxi-Gel^™^ (Pierce, Rockford, IL, USA), according to manufacturer's instruction to remove endotoxin of proteins. We measured the amount of endotoxin in the proteins (\< 0.03 EU/ml) using a Limulus amoebocyte lysate assay (BioWhitaker, Walkersville, MD, USA). The protein concentration was determined using the Bradford assay ([@b41-bmb-51-654]).

To assess the transduction of Tat-ATOX1, Raw 264.7 cells were treated with varying concentrations of Tat-ATOX1 or control ATOX1 (0.01--0.3 μM) for 1 h. Some cells were treated with Tat-ATOX1 or control ATOX1 at one concentration (0.3 μM) for various times (15--60 min). Cells were treated with trypsin-EDTA, washed with phosphate-buffered saline (PBS) and harvested to perform Western blot analysis.

Western blot analysis
---------------------

Western blot analysis was performed, as described previously ([@b24-bmb-51-654], [@b42-bmb-51-654]). Equal amounts of sample proteins were separated with 15% SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was blocked with 5% nonfat dry milk in TBST buffer (25 mM Tris-HCl, 140 mM NaCl, 0.1% Tween 20, pH 7.5) for 1 h. The membranes were immunoblotted with the indicated primary and HRP-conjugated secondary antibodies, as recommended by the manufacturer. The protein bands were detected using enhanced chemiluminescent reagents (Amersham, Franklin Lakes, NJ, USA).

Fluorescence microscopy analysis
--------------------------------

Fluorescence microscopy analysis was performed as described previously ([@b24-bmb-51-654], [@b35-bmb-51-654]). Raw 264.7 cells were grown on coverslips and treated with 0.3 μM of Tat-ATOX1 protein for 1 h at 37°C. Then, the cells were washed twice with PBS and fixed with 4% paraformaldehyde for 5 min at room temperature. The cells were permeabilized and blocked for 40 min with 3% bovine serum albumin, 0.1% Triton X-100 in PBS (PBS-BT) and washed with PBS-BT. The primary antibody (Histidine) was diluted 1:2000, and incubated for 1 h at room temperature. The secondary antibody (Alexa Fluor 488, Invitrogen) was diluted 1:15000, and incubated for 1 h at room temperature in the dark. Nuclei were stained for 2 min with 1 μg/ml DAPI (Roche). The distributions of fluorescence were analyzed using a fluorescence microscope (Nikon Eclipse 80i; Nikon, Tokyo, Japan).

Measurement of ROS levels
-------------------------

Raw 264.7 cells were incubated in the absence or presence of Tat-ATOX1 (0.3 μM) for 1 h, and then treated with LPS (1 μg/ml) for 30 min. Cells were then washed twice with PBS and incubated with DCF-DA (20 μM) for 15 min. 2′,7′-dichloro-fluorescein diacetate (DCF-DA) staining was performed according to the manufacturer's instructions ([@b24-bmb-51-654], [@b35-bmb-51-654]). Images were taken using a fluorescence microscope (Nikon eclipse 80i, Japan).

TPA-induced mouse ear edema model
---------------------------------

Male ICR mice were housed at constant temperature (23°C) and relative humidity (60%) with a fixed 12 h light:12 h dark cycle and free access to food and water. All experimental procedures involving animals and their care conformed to the Guide for the Care and Use of Laboratory Animals of the National Veterinary Research and Quarantine Service of Korea and were approved by the Hallym Medical Center Institutional Animal Care and Use Committee.

TPA-induced mouse ear edema models were prepared as described previously ([@b35-bmb-51-654]). To examine the effects of Tat-ATOX1 against TPA-induced ear edema, the mice were divided into four groups (n = 5 per group). The experimental groups were as follows: 1) normal control mice, 2) TPA-induced ear edema mice, 3) TPA + control ATOX1 treated mice, and 4) TPA + Tat-ATOX1 treated mice. TPA (1.0 μg) dissolved in 20 μl of acetone was applied to the inner and outer surfaces of the mice ears every day for 3 days. Tat-ATOX1 (10 μg) protein was topically applied to the mice ears every day for 1 h after TPA treatment. After the final treatment with TPA and Tat-ATOX1, mice were sacrificed, and ear biopsies were obtained. Ear thicknesses were measured using a digital thickness gauge (Mitutoyo Corporation, Toyko, Japan). Ear weights were measured after 5 mm diameter ear biopsies were obtained from each group using a punch (Kai Industries, Gifu, Japan). For histological analyses, ear biopsies were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned at a thickness of 5 μm, then stained with hematoxylin and eosin.

Statistical analysis
--------------------

Data represent the mean of three experiments ± SD. Differences between groups were analyzed by one-way analysis of variance followed by a Bonferroni's post-hoc test using GraphPad Prism software (version 5.01; GraphPad Software Inc., San Diego, CA, USA). \*P \< 0.01 was considered to indicate a statistically significant difference.
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![Transduction of Tat-ATOX1 into Raw 264.7 cells. Tat-ATOX1 (0.01--0.3 μM) was added to the culture media for 1 h (A), Tat-ATOX1 (0.3 μM) was added to the culture media for 15--60 min (B), cells were treated with 0.3 μM of Tat-ATOX1 and incubated for 1--15 h and analyzed by Western blotting (C) and band intensities were measured by densitometry. The cells were treated with Tat-ATOX1 (0.3 μM) for 1 h and distribution of transduced Tat-ATOX1 was confirmed by fluorescence microscopy (D). The effect of Tat-ATOX1 against LPS-induced ROS production in Raw 264.7 cells. Intracellular ROS levels were measured after staining with DCF-DA (E). Scale bar = 50 μm.](bmb-51-654f1){#f1-bmb-51-654}

![Effects of Tat-ATOX1 on LPS-induced inflammatory responses in Raw 264.7 cells. The cells were pretreated with Tat-ATOX1 (0.3 μM) for 1 h, then treated with LPS (1 μg/ml). Expression levels of COX-2 and iNOS protein (A), NF-κB (B) and MAPK (C) activation were determined by Western blotting. The band intensity was measured by densitometry. \*P \< 0.01, compared to LPS-treated cells.](bmb-51-654f2){#f2-bmb-51-654}

![Effects of Tat-ATOX1 on ear edema in a TPA-induced mice model. Ears of mice were exposed to TPA (1 μg/ear). Tat-ATOX1 (10 μg) was topically applied to mice ears 1 h after TPA treatment for 3 days. The inhibition of TPA-induced ear edema was analyzed by hematoxylin and eosin immunostaining (A), changes in ear thickness (B), and ear weights (C). Scale bar = 50 μm (top panel) and 25 μm (bottom panel). \*P \< 0.01, compared to TPA-treated mice.](bmb-51-654f3){#f3-bmb-51-654}

![Effect of Tat-ATOX1 against TPA-induced pro-inflammatory mediator proteins (COX-2 and iNOS), NF-κB and MAPK activation in mice ears. Tat-ATOX1 (10 μg) was topically applied to mice ears 1 h after daily treatment with TPA (1 μg/ear) for 3 days. After ear biopsies were prepared, the expression levels of pro-inflammatory mediator proteins (A), NF-κB (B) and MAPK (C) activation were analyzed by Western blotting. Band intensities were measured by densitometry. \*P \< 0.01, compared to TPA-treated mice.](bmb-51-654f4){#f4-bmb-51-654}
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